Literature DB >> 21688989

The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study.

Joaquín Pérez-Guisado1, Andrés Muñoz-Serrano.   

Abstract

The "Spanish Ketogenic Mediterranean Diet" (SKMD) has been shown to be an effective and safe way to cure patients suffering from metabolic syndrome (MS). Keeping in mind that nonalcoholic fatty liver disease (NAFLD) is closely associated with MS, the purpose of this study was to evaluate the potential therapeutic properties under free living conditions of the SKMD in patients with MS (following the International Diabetes Federation [IDF] consensus guidelines) and NAFLD (suspected by using a cutoff value of alanine aminotransferase [ALT] levels of >40 U/L and confirmed by abdominal ultrasonography) over a 12-week period. A prospective study was carried out in 14 obese men meeting the inclusion criteria and whose body mass index (BMI) and age were 36.58±0.54 kg/m² and 41.18±2.28 years, respectively. Statistical differences between the parameters studied before and after administration of the SKMD (week 0 and 12) were analyzed by paired Student's t test (continuous variables) and the χ² test (discontinuous variables). P<.05 was considered statistically significant. There was an extremely significant (P<.001) improvement in body weight (from 109.79 kg to 95.86 kg), low-density lipoprotein-cholesterol (from 123.43 mg/dL to 100.35 mg/dL), ALT (from 71.92 U/L to 37.07 U/L), aspartate aminotransferase (from 47.71 U/L to 29.57 U/L), steatosis degree (complete fatty liver regression was observed in 21.4% of the patients, and an overall reduction was found in 92.86% of the patients), and all the parameters studied associated with the MS: BMI (from 36.99 kg/m² to 32.42 kg/m²), waist circumference (from 114.01 cm to 98.59 cm), fasting plasma glucose (from 118.57 mg/dL to 90.14 mg/dL), triacylglycerols (from 232.64 mg/dL to 111.21 mg/dL), high-density lipoprotein-cholesterol (HDLc) (from 42.81 mg/dL to 58.71 mg/dL), systolic blood pressure (from 142.86 mm Hg to 125.36 mm Hg), and diastolic blood pressure (from 89.64 mm Hg to 77.86 mm Hg). After the diet all the subjects were free of MS according to the IDF definition, and 100% of them had normal triacylglycerols and HDLc levels, in spite of the fact that 100% of them still had a BMI of >30 kg/m². We conclude that the SKMD could be an effective and safe way to treat patients suffering from MS and the associated NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688989     DOI: 10.1089/jmf.2011.0075

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  21 in total

1.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 2.  Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease.

Authors:  Raja Gopal Reddy Mooli; Sadeesh K Ramakrishnan
Journal:  Front Physiol       Date:  2022-07-04       Impact factor: 4.755

Review 3.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 4.  Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?

Authors:  Francesco Sofi; Alessandro Casini
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 5.  Ketogenic diets and pain.

Authors:  Susan A Masino; David N Ruskin
Journal:  J Child Neurol       Date:  2013-05-16       Impact factor: 1.987

6.  Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet.

Authors:  Rebecca C Schugar; Xiaojing Huang; Ashley R Moll; Elizabeth M Brunt; Peter A Crawford
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

7.  The nervous system and metabolic dysregulation: emerging evidence converges on ketogenic diet therapy.

Authors:  David N Ruskin; Susan A Masino
Journal:  Front Neurosci       Date:  2012-03-26       Impact factor: 4.677

Review 8.  Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss.

Authors:  Violeta B Popov; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

9.  Ketogenic diet improves core symptoms of autism in BTBR mice.

Authors:  David N Ruskin; Julia Svedova; Jessica L Cote; Ursula Sandau; Jong M Rho; Masahito Kawamura; Detlev Boison; Susan A Masino
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

10.  Ketogenic diets, physical activity and body composition: a review.

Authors:  Damoon Ashtary-Larky; Reza Bagheri; Hoda Bavi; Julien S Baker; Tatiana Moro; Laura Mancin; Antonio Paoli
Journal:  Br J Nutr       Date:  2021-07-12       Impact factor: 4.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.